A Prospective, Multi-center, Cohort Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Therapy in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 21 Dec 2016
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B; Liver cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 16 Dec 2016 Planned End Date changed from 1 Nov 2020 to 1 Jan 2021.
- 16 Dec 2016 Planned primary completion date changed from 1 Nov 2020 to 1 Jan 2021.
- 16 Dec 2016 Status changed from recruiting to active, no longer recruiting.